Pharvaris director sells 8,667 shares in plan
Pharvaris N.V. director Robert Glassman exercised and sold 8,667 shares in a cashless, pre-planned Rule 10b5-1 transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Pharvaris N.V. (PHVS) director Robert Glassman reported a cashless exercise and sale of stock options on September 15, 2026. He exercised options for 8,667 shares of common stock at an exercise price of $22.31 per share and sold the same 8,667 shares at a weighted average price of $38.2735 per share, with individual sale prices ranging from $38.175 to $38.43. The option, which expires April 11, 2034, was fully exercised in this transaction, and the transactions were made under a Rule 10b5-1 trading plan.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,667 shares ($138K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Glassman Robert
Role
Director
Sold
8,667 shs ($332K)
Approx. gross sale proceeds
$332K
Approx. exercise cost
$193K
Approx. pre-tax spread
$138K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F3 | 8,667 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 8,667 | $22.31 | $193K |
| Sale | Common Stock F1, F2 | 8,667 | $38.2735 | $332K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 10,500 shares (Direct)
Footnotes (3)
- F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
- F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $38.175 to $38.43. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3. 100% of the option vest on the 12-month anniversary.
Key Figures
Shares exercised: 8,667 shares
Exercise price: $22.31 per share
Weighted average sale price: $38.2735 per share
+3 more
6 metrics
Shares exercised
8,667 shares
Options exercised into Pharvaris N.V. common stock on September 15, 2026
Exercise price
$22.31 per share
Strike price of stock options exercised for 8,667 shares
Weighted average sale price
$38.2735 per share
Average price for 8,667 shares of Pharvaris N.V. sold on September 15, 2026
Sale price range
$38.175 to $38.43 per share
Range of prices for multiple sale transactions on September 15, 2026
Option expiration date
April 11, 2034
Expiration of the stock option that was fully exercised
Net shares sold
8,667 shares
Shares sold in excess of purchases in the reported transactions
Key Terms
Rule 10b5-1 trading plan, cashless exercise, weighted average sale price
3 terms
Rule 10b5-1 trading plan regulatory
"transactions on the reported date pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
cashless exercise financial
"shares were sold in connection with the exercise of stock options in a cashless exercise"
A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.
weighted average sale price financial
"The reported price represents a weighted average sale price for shares sold"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pharvaris N.V. (PHVS) director Robert Glassman report in this Form 4?
He reported a cashless exercise of options for 8,667 Pharvaris N.V. shares at $22.31 per share and the sale of all 8,667 shares at a weighted average price of $38.2735 per share on September 15, 2026, under a Rule 10b5-1 plan.
What was the exercise price of the options exercised by the PHVS director?
The options exercised by Robert Glassman to acquire Pharvaris N.V. shares had an exercise price of $22.31 per share. He exercised options covering 8,667 shares of common stock and then sold all of those shares in a cashless exercise transaction.
Were Robert Glassman’s PHVS transactions made under a Rule 10b5-1 trading plan?
Yes. The filing indicates the transactions were made pursuant to a Rule 10b5-1 trading plan. Footnotes state it was a scheduled exercise and sale and that the sales were executed under a Rule 10b5-1 trading plan, reducing the significance of trade timing as an information signal.
What is the expiration date of the Pharvaris N.V. stock option exercised?
The stock option exercised by Robert Glassman had an expiration date of April 11, 2034. The transaction on September 15, 2026, exercised 100% of this option grant, covering 8,667 shares of Pharvaris N.V. common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
